IL2 and systemic lupus erythematosus: Iberdomide's clinical efficacy in SLE correlated with a reduction in the type I IFN gene signature. The drug selectively rebalanced immune abnormalities by suppressing type I IFN and B cell pathways while elevating IL‐2 and Tregs.